Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

9(60%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

40%

Ph phase_1

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution15 total trials

Phase 1Safety & dosage

9(60.0%)

Phase 2Efficacy & side effects

6(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(11)

Completed(3)

Other(1)

Detailed Status

Active, not recruiting5

Recruiting4

Completed3

Not yet recruiting2

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 19 (60.0%)

Phase 26 (40.0%)

Trials by Status

unknown17%

completed320%

not_yet_recruiting213%

recruiting427%

active_not_recruiting533%

Recent Activity

9 active trials

Showing 5 of 15

active_not_recruitingphase_2

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

NCT05227664

active_not_recruitingphase_1

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

NCT05229497

completedphase_1

Clinical Trials (15)

Showing 15 of 15 trials

NCT05227664Phase 2

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Active Not Recruiting

NCT05229497Phase 1

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Active Not Recruiting

NCT05214482Phase 1

A Study of AK112 in Advanced Malignant Tumors

Completed

NCT07245446Phase 2

A Study of Ivonescimab in First-Line ES-SCLC

Recruiting

NCT05382442Phase 2

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active Not Recruiting

NCT04980885Phase 1

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Active Not Recruiting

NCT04728334Phase 1

A Phase 1 Dose Escalation and Expansion Study of AK117

Completed

NCT04900350Phase 1

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

Active Not Recruiting

NCT06642792Phase 1

A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

Recruiting

NCT06196203Phase 2

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting

NCT04349969Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104

Completed

NCT06508606Phase 2

AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC

Not Yet Recruiting

NCT06387420Phase 1

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

Not Yet Recruiting

NCT05960955Phase 2

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting

NCT05235542Phase 1

A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors

Unknown

All 15 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 15